ELOXX PHARMACEUTICALS, INC.: total liabilities
Total liabilities for ELOXX PHARMACEUTICALS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All ELOXX PHARMACEUTICALS, INC. financial histories
What this measure means
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
Exact concept: us-gaap:Liabilities. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2011-06-30 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 17,177,000 | USD | 2026-03-17 | 10-K · 0001193125-26-108687 |
| At date | 2024-12-31 | 27,311,000 | USD | 2026-03-17 | 10-K · 0001193125-26-108687 |
| At date | 2023-12-31 | 24,311,000 | USD | 2026-03-17 | 10-K · 0001193125-26-108687 |
| At date | 2022-12-31 | 31,783,000 | USD | 2023-03-31 | 10-K · 0000950170-23-011360 |
| At date | 2021-12-31 | 22,755,000 | USD | 2023-03-31 | 10-K · 0000950170-23-011360 |
| At date | 2020-12-31 | 16,247,000 | USD | 2022-03-30 | 10-K · 0001564590-22-012683 |
| At date | 2019-12-31 | 22,734,000 | USD | 2021-03-12 | 10-K · 0001564590-21-012703 |
| At date | 2018-12-31 | 7,807,000 | USD | 2020-03-06 | 10-K · 0001564590-20-009148 |
| At date | 2017-06-30 | 4,973,994 | USD | 2017-10-13 | 10-K · 0001144204-17-052475 |
| At date | 2016-06-30 | 4,665,294 | USD | 2017-10-13 | 10-K · 0001144204-17-052475 |
| At date | 2015-06-30 | 7,322,601 | USD | 2016-10-13 | 10-K · 0001144204-16-128038 |
| At date | 2014-06-30 | 5,844,899 | USD | 2015-10-09 | 10-K · 0001144204-15-058919 |
| At date | 2013-06-30 | 3,311,670 | USD | 2014-09-29 | 10-K · 0001144204-14-058176 |
| At date | 2012-06-30 | 3,501,841 | USD | 2013-09-11 | 10-K · 0001144204-13-050259 |
| At date | 2011-06-30 | 4,079,426 | USD | 2012-10-26 | 10-K/A · 0001144204-12-057875 |
Related financial histories
- ELOXX PHARMACEUTICALS, INC.: total assets
- ELOXX PHARMACEUTICALS, INC.: stockholders equity
- ELOXX PHARMACEUTICALS, INC.: cash and cash equivalents
- ELOXX PHARMACEUTICALS, INC.: net income or loss
- ELOXX PHARMACEUTICALS, INC.: operating cash flow
- ELOXX PHARMACEUTICALS, INC.: capital expenditure payments
- ELOXX PHARMACEUTICALS, INC.: revenue
- ELOXX PHARMACEUTICALS, INC.: financing cash flow
- ELOXX PHARMACEUTICALS, INC.: investing cash flow
- ELOXX PHARMACEUTICALS, INC.: retained earnings or deficit
- ELOXX PHARMACEUTICALS, INC.: basic weighted-average shares
- ELOXX PHARMACEUTICALS, INC.: diluted weighted-average shares
- ELOXX PHARMACEUTICALS, INC.: basic earnings per share
- ELOXX PHARMACEUTICALS, INC.: diluted earnings per share
- ELOXX PHARMACEUTICALS, INC.: income tax expense or benefit
- ELOXX PHARMACEUTICALS, INC.: net property, plant and equipment
- ELOXX PHARMACEUTICALS, INC.: share-based compensation expense
- ELOXX PHARMACEUTICALS, INC.: operating income or loss
- ELOXX PHARMACEUTICALS, INC.: current assets
- ELOXX PHARMACEUTICALS, INC.: current liabilities
- ELOXX PHARMACEUTICALS, INC.: current accounts payable
- ELOXX PHARMACEUTICALS, INC.: goodwill carrying amount
- ELOXX PHARMACEUTICALS, INC.: net finite-lived intangible assets
- ELOXX PHARMACEUTICALS, INC.: net current accounts receivable
- ELOXX PHARMACEUTICALS, INC.: operating expenses
- ELOXX PHARMACEUTICALS, INC.: research and development expense
Inspect the source
- Entity
- ELOXX PHARMACEUTICALS, INC. / CIK 0001035354
- Captured
- 2026-09-20T05:15:09.498Z
- SEC response SHA-256
b351a9ed06ee3e6f1d738bbdb3852b866526fe561e11a7ffd4a81bc43bb27195
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001035354.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))